Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and diagnostics, cross lab operations consisting of consumables and services, and applied end markets. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.
Last trade$172.28
Day change-$0.64 (-0.37%)
Day range$171.27 – $174.11
Volume849,048
Market cap$48.75B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$48.75B
Price / earnings
33.85×
Price / book
6.62×
Price / sales
6.61×
EV / sales
6.91×
EV / EBITDA
26.67×
Profitability
Earnings per share
$5.11
Return on assets
10.31%
Return on equity
19.56%
Dividend yield
0.59%
Liquidity and leverage
Debt / equity
0.54×
Current ratio
2.05×
Quick ratio
1.56×
Cash ratio
0.77×
Cash flow
Price / cash flow
30.3×
Price / free cash flow
38.48×
Free cash flow
$1.27B
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for A, quarterly periods
Line item
Q3 FY2026 Jul 31, 2026
Q2 FY2026 Apr 30, 2026
Q1 FY2026 Jan 31, 2026
Q4 FY2025 Oct 31, 2025
Q3 FY2025 Jul 31, 2025
Q2 FY2025 Apr 30, 2025
Q1 FY2025 Jan 31, 2025
Q4 FY2024 Oct 31, 2024
Revenue
$1.88B
$1.84B
$1.8B
$1.86B
$1.74B
$1.67B
$1.68B
$1.7B
Cost of revenue
$836M
$845M
$852M
$871M
$850M
$802M
$782M
$785M
Gross profit
$1.04B
$990M
$946M
$990M
$888M
$866M
$899M
$916M
Selling, general and administrative
$475M
$465M
$476M
$428M
$417M
$454M
$410M
$397M
Research and development
$123M
$126M
$117M
$119M
$111M
$112M
$113M
$111M
Total operating expenses
$598M
$591M
$593M
$547M
$528M
$566M
$523M
$508M
Operating income
$444M
$399M
$353M
$443M
$360M
$300M
$376M
$408M
Interest expense
-$29M
-$25M
-$25M
-$27M
-$28M
-$29M
-$28M
-$32M
Income before taxes
$444M
$408M
$364M
$442M
$366M
$260M
$367M
$401M
Income taxes
$82M
$69M
$59M
$8M
$30M
$45M
$49M
$50M
Net income
$362M
$339M
$305M
$434M
$336M
$215M
$318M
$351M
Net income attributable to common shareholders
$362M
$339M
$305M
$434M
$336M
$215M
$318M
$351M
EBITDA
$510M
$466M
$420M
$514M
$432M
$373M
$448M
$477M
Basic earnings per share
$1.28
$1.20
$1.08
$1.54
$1.18
$0.75
$1.12
$1.24
Diluted earnings per share
$1.28
$1.20
$1.07
$1.53
$1.18
$0.75
$1.11
$1.23
Recent news
Company coverage with links to the original publishers.
NRx Pharmaceuticals reported a Q3 loss of $0.05 per share, beating expectations of $0.29 loss, but missed revenue estimates with $1.16 million versus consensus. The company received a Zacks Rank #5 (Strong Sell) rating due to unfavorable estimate revisions, and shares have underperformed the S&P 500 by 29.7% year-to-date.
Agilent Technologies is expected to report Q4 2026 earnings on November 23, with consensus estimates of $1.72 EPS (up 8.2% YoY) and $1.98B in revenues (up 6.7% YoY). However, with a Zacks Rank of #4 and a modest Earnings ESP of +0.31%, the company is not considered a compelling earnings-beat candidate. While Agilent beat estimates by 9.46% in the last quarter, the current combination of metrics makes it difficult to predict an earnings surprise.
Aveanna Healthcare reported Q3 2026 earnings of $0.23 per share, beating consensus estimates of $0.20, with revenues of $695.54 million exceeding expectations by 1.81%. The company has outperformed market estimates in four consecutive quarters and gained 60.2% year-to-date. Aveanna received a Zacks Rank #2 (Buy) rating with favorable estimate revision trends. Meanwhile, Agilent Technologies is expected to report Q3 2026 results on November 23, with projected earnings of $1.72 per share (+8.2% YoY) and revenues of $1.99 billion (+6.7% YoY), though consensus estimates were revised 1% lower in the last 30 days.
The global nucleic acid labeling market is projected to grow from $1.7 billion in 2025 to $2.8 billion by 2032, expanding at a 7% CAGR. Growth is driven by advances in genomics, molecular diagnostics, NGS, and high-throughput laboratory workflows. Key applications include oligonucleotide labeling and in-situ hybridization, with the U.S. and China representing major regional markets.
Align Technology (ALGN) reported Q3 2026 earnings of $2.80 per share (up 7.3%) and revenues of $1.01 billion (up 1.9%), both beating estimates. Clear Aligner shipments grew 6.6% to a record level, supported by strong international growth and improved doctor utilization. However, Systems revenues declined 7.6% due to pricing pressure from lower-priced scanner configurations. The company cut its 2026 revenue guidance to $4.11-$4.13 billion, citing softer Systems and Services expectations and lower Clear Aligner ASP assumptions, causing shares to fall 0.7% after-hours.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
Oct 6, 2026
$0.255
Oct 28, 2026
recurring
Jun 30, 2026
$0.255
Jul 22, 2026
recurring
Mar 31, 2026
$0.255
Apr 22, 2026
recurring
Jan 6, 2026
$0.255
Jan 28, 2026
recurring
Sep 30, 2025
$0.248
Oct 22, 2025
recurring
Stock splits
Historical share-structure events and their execution dates.